Insilico Medicine, a clinical-stage biotech firm specializing in AI-driven drug discovery, has announced a collaboration with Eli Lilly to develop new therapeutics. This partnership grants Lilly an exclusive license for certain preclinical drug candidates and combines Insilico’s advanced AI platforms with Lilly’s extensive development expertise. The agreement involves an initial payment of $115 million, potentially escalating to $2.75 billion with further milestones and royalties. Both companies aim to leverage their strengths to create transformative therapies for diseases with significant unmet needs.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://vir.com.vn/insilico-medicine-partners-with-lilly-on-drug-discovery-collaboration-149527.html
